OCCIDENT logo

OCCIDENT

Europe, Bayern, Germany, Munich

Description

OCCIDENT is a Munich-based entrepreneurial venture capital investor, operating as a family-owned investment company. With a strong focus on deep tech, OCCIDENT positions itself as a long-term partner for innovative startups, providing not just capital but also strategic guidance and access to its extensive network. Their investment philosophy is rooted in a commitment to fostering groundbreaking technologies and supporting visionary founders from the early stages of their development.

The firm primarily targets early-stage companies, spanning from seed to Series B rounds, with a clear emphasis on high-potential deep tech sectors. Their core investment areas include Life Sciences, Medical Technology, Diagnostics, Industrial Tech, and Digital solutions. OCCIDENT seeks out companies that are developing disruptive technologies with significant market potential and a clear path to commercialization, often leveraging complex scientific or engineering breakthroughs.

OCCIDENT's investment strategy involves initial cheque sizes that typically range from EUR 0.5 million to EUR 5 million per round, demonstrating their commitment to providing substantial early-stage capital. Beyond the initial investment, they are known for their willingness to participate in follow-on rounds, supporting their portfolio companies through various growth phases. As of recent reports, OCCIDENT has built a robust portfolio comprising more than 30 innovative companies, underscoring their active role in the European deep tech ecosystem. This extensive portfolio reflects their consistent engagement and belief in the long-term value creation of their chosen sectors.

Investor Profile

OCCIDENT has backed more than 38 startups, with 1 new investments in the last 12 months alone. The firm has led 12 rounds, about 32% of its total and boasts 3 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series B, Seed rounds (top funding stages).
  • Majority of deals are located in Switzerland, Germany, Finland.
  • Strong thematic focus on Health Care, Biotechnology, Medical Device.
  • Typical check size: $540K – $5.4M.

Stage Focus

  • Series A (32%)
  • Series B (18%)
  • Seed (16%)
  • Series C (13%)
  • Series Unknown (11%)
  • Series D (8%)
  • Convertible Note (3%)

Country Focus

  • Switzerland (58%)
  • Germany (37%)
  • Finland (3%)
  • Slovenia (3%)

Industry Focus

  • Health Care
  • Biotechnology
  • Medical Device
  • Life Science
  • Therapeutics
  • Health Diagnostics
  • Medical
  • Pharmaceutical
  • Software
  • Network Security
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does OCCIDENT frequently co-invest with?

BioMedPartners
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 3
Zürcher Kantonal Bank
Europe, Zurich, Switzerland, Zürich
Co-Investments: 11
Seventure Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 3
HTGF | High-Tech Gruenderfonds
Europe, Nordrhein-Westfalen, Germany, Bonn
Co-Investments: 13
H
Europe, Basel-Landschaft, Switzerland, Liestal
Co-Investments: 4
Verve Ventures
Europe, Zug, Switzerland, Zug
Co-Investments: 5
Alpana Ventures
Europe, Geneve, Switzerland, Geneva
Co-Investments: 5
coparion
Europe, Nordrhein-Westfalen, Germany, Cologne
Co-Investments: 3
Bayern Kapital
Europe, Bayern, Germany, Landshut
Co-Investments: 6
redalpine
Europe, Zurich, Switzerland, Zürich
Co-Investments: 4

Which angels does OCCIDENT often collaborate with?

Marius Nacht
Asia, Tel Aviv, Israel, Tel Aviv-yafo
Shared Deals: 1
TT
Europe, Slovenia
Shared Deals: 1
JG
Europe, Zurich, Switzerland
Shared Deals: 1
TD
North America, Washington, United States, Seattle
Shared Deals: 1
JS
Europe, Zurich, Switzerland, Zürich
Shared Deals: 1
JA
Europe, Hessen, Germany, Frankfurt
Shared Deals: 1
Shared Deals: 1
RC
Europe, England, United Kingdom, London
Shared Deals: 1

What are some of recent deals done by OCCIDENT?

Lymphatica Medtech

Ecublens, Vaud, Switzerland

Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.

BiotechnologyHealth CareMedicalMedical Device
Series BOct 8, 2024
Amount Raised: $19,646,128
Hemotune

Zürich, Zurich, Switzerland

Hemotune is a medical device company that develops a therapeutic blood purification platform for treatment of health ailments.

BiotechnologyHealth CareLife ScienceMedical DeviceTherapeutics
Series BMar 25, 2024
Amount Raised: $15,562,645
Tubulis

Munich, Bayern, Germany

Tubulis is a chemotherapeutic medication developer specializing in cancer and chronic disease treatment.

BiotechnologyHealth CareLife SciencePharmaceuticalTherapeutics
Series BMar 14, 2024
Amount Raised: $139,300,472
Altavo

Dresden, Sachsen, Germany

Altavo operates as a medical device startup.

Health CareManufacturingMedical Device
Series AFeb 20, 2024
Amount Raised: $5,404,950
Chipmetrics

Joensuu, Eastern Finland, Finland

Nanotechnology, metrology

ElectronicsManufacturing
SeedJan 24, 2024
Amount Raised: $2,611,512
ReCatalyst

Ljubljana, Ljubljana Urban Commune, Slovenia

ReCatalyst develops next-generation PEM fuel cell catalysts.

ChemicalNanotechnology
SeedJul 12, 2023
Amount Raised: $1,893,895
EBAMed

Geneva, Geneve, Switzerland

EBAMed develops innovative solutions for non-invasive and automated treatment of heart arrhythmias by using ion beams.

Health Care
Series AJun 27, 2023
Amount Raised: $15,724,080
Lunaphore

Lausanne, Vaud, Switzerland

Lunaphore is a life sciences company that is creating technologies to enable spatial biology in all laboratories.

BiotechnologyHealth CareHealth DiagnosticsLife ScienceMedical Device
Series DMar 23, 2023
Amount Raised: $32,724,369
iThera Medical

München, Bayern, Germany

iThera Medical focuses on the development of proprietary MSOT technology for use in preclinical and clinical applications.

BiotechnologyHealth CareMedical
Series DDec 21, 2022
Amount Raised: $13,790,470
Resistell AG

Basel, Basel-Stadt, Switzerland

Resistell is a antibiotic resistance test.

Medical Device
Series BDec 20, 2022
Amount Raised: $9,175,580